Progress in diagnosis and treatment of AL-type myocardial amyloidosis
Zhu Jialiang1,2 Li Guohua2
1.Graduate School of Shandong First University, Shandong Provicne, Taian 271000, China;
2.the Second Department of Cardiology, Qianfoshan Hospital, Shandong Province, Ji′nan 250000, China
Abstract：The mechanism of myocardial amyloidosis is the deposition of insoluble amyloid in myocardial tissue，a disease that causes cardiac dysfunction such as impaired myocardial electrical activity, cardiac hypertrophy, increased myocardial stiffness, and decreased diastolic function. Primary amyloidosis and amyloidosis associated with plasma cell disease are all immunoglobulin light chains, so they are collectively referred to as AL-type amyloidosis. Early symptoms of myocardial amyloidosis are not obvious, but as the disease progresses, symptoms of myocardial diastolic function may appear, which often indicates poor prognosis. Among them, AL-type myocardial amyloidosis is more common than other types, so this article focuses on the early clinical manifestations, staging and prognosis ,treatment of AL-type myocardial amyloidosis.
[1] García-Pavía P，Tomé-Esteban MT. Amyloidosis also a heart disease [J]. Revista espa?觡ola de cardiologi?觃，2011，64（9）：797-808.
[2] 张燕，任艺虹，钱赓，等.62例心肌淀粉样变性患者的临床特点及预后分析[J].解放军医学院学报，2013，34（3）：211-213.
[3] Dispenzieri A，Gertz MA，Kyle RA，et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide：a staging system for primary systemic amyloidosis [J]. J Clin Oncol，2004，22（18）：3751-3757.
[4] Sher T. Recent advances in the diagnosis and management of cardiac amyloidosis [J]. Future Cardiol，2014，10（1）：131-146.
[5] Falk RH，Alexander KM，Liao R. AL （light-chain） cardiac amyloidosis：a review of diagnosis and therapy [J]. J Am Coll Cardiol，2016，68（12）：1323-1341.
[6] 程中伟，田庄，康琳，等.心脏淀粉样变患者的心电图和心脏超声特点[J].中华心血管病杂志，2010，38（7）：606-609.
[7] Phelan D，Collier P，Thavendiranathan P，et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis [J]. Heart，2012，98（19）：1442-1448.
[8] White JA，Kim Hw，shah D，et a1. CMR image with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis [J]. JACC Cardiovasc Image，2014，7（2）：143-156.
[9] Dorbala S，Vangala D，Semer J，et al. Imaging cardiac amyloidosis：a pilot study using 18F-florbetapir positron emission tomography [J] Euro J nuclear med molecul imag，2014，41（9）：1652-1662.
[10] Kumar S，Dispenzieri A，Lacy MQ，et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements [J]. J Clin Oncol，2012，30（9）：989-995.
[11] Wechalekar AD，Schonland SO，Kastritis E，et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage Ⅲ AL amyloidosis [J]. Blood，2013，121（17）：3420-3427.
[12] 黄栩芾，冯俊，张聪丽，等.梅奥分期系统在中国原发性轻链型淀粉样变患者中的临床应用价值[J].中华血液学杂志，2016，37（4）：278-282.
[13] 张焰，饶莉.心脏淀粉样变性诊疗进展[J].心血管病学进展，2015，36（5）：527-530.
[14] Cappelli F，Porciani MC，Bergesio F，et al. Right ventricular function in AL amyloidosis：characteristics and prognostic implication [J]. Eur Heart J Cardiovascul Imaging，2012，13（5）：416-422.
[15] Falk RH，Comenzo RL. The systemic amyloidosis [J]. N Eng J Med，1997，337（13）：898-909.
[16] Shah KB，Inoue Y. Amyloidosis and the heart：a comprehensive review [J]. Archives Inter Med，2006，166（17）：1805-1813.
[17] Libby P，Bonow RO，Mann DL，et al. Braunwald′s Heart Disease [M]. 8th Ed. St. Louis：Saunders，an Imprint of Elsevier，2007.
[18] Falk RH. Diagnosis and management of the cardiac amyloidosis [J]. Circul，2005，112（13）：2047-2060.
[19] Kristen AV，Dengler TJ，Hegenbart U，et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death [J]. Heart Rhythm，2008，5（2）：235-240.
[20] Palladini G，Russo P，Lavatelli F，et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan，dexamethasone，and thalidomide [J]. Annal Hematol，2009，88（4）：347-350.
[21] Mahmood S，Palladini G，Sanchorawala V. Update on treatment of light chain amyloidosis [J]. Haematol，2014，99（2）：209-221.
[22] Gertz MA，Lacy MQ，Dispenzieri A，et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis [J]. Bone Marrow Transplantation，2013，48（4）：557-561.
[23] Sanchorawala V，Quillen K，Sloan JM，et al. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis：a pilot study [J]. Haematol，2011，96（12）：1890-1892.
[24] 路瑾，王辉，黄晓军.硼替佐米联合地塞米松、环磷酰胺治疗原发系统性淀粉样变性疗效观察[J].中华血液学杂志，2013，34（4）：345-348.
[25] Venner CP，Lane T，Foard D，et al. Cyclophosphamide，bortezomib，and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival [J]. Blood，2012，119（19）：4387-4390.
2019, Vol. 16 
京公网安备 11010502046598号